Status:
UNKNOWN
Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions
Lead Sponsor:
Sohag University
Conditions:
Variable Endometrial Lesions
Eligibility:
FEMALE
25-80 years
Brief Summary
Endometrial carcinoma (EC) is the 6th most commonly occurring cancer in women and the 15th most common cancer overall According to facts derived from Globocan for the year 2020.The overall incidence w...
Eligibility Criteria
Inclusion
- 1\. Specimens of total abdominal hysterectomy and bilateral salpingio-oopherectomy of endometrial carcinoma patients 2. D\&C of endometrial tissue suspected of hyperplastic or neoplastic lesions
Exclusion
- • Specimens with insufficient clinical data.
- Specimens with extensive necrosis
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06132230
Start Date
December 1 2023
End Date
December 1 2025
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag faculty of Medicine
Sohag, Egypt